Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Non Operating Income (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Non Operating Income for 7 consecutive years, with $181000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Non Operating Income rose 341.46% to $181000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $632000.0, a 19.47% increase, with the full-year FY2024 number at $632000.0, up 19.47% from a year prior.
  • Non Operating Income was $181000.0 for Q4 2024 at SELLAS Life Sciences, down from $221000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $221000.0 in Q3 2024 to a low of $41000.0 in Q4 2023.
  • A 3-year average of $149400.0 and a median of $166000.0 in 2024 define the central range for Non Operating Income.
  • Biggest YoY gain for Non Operating Income was 341.46% in 2024; the steepest drop was 57.07% in 2024.
  • SELLAS Life Sciences' Non Operating Income stood at $124000.0 in 2022, then plummeted by 66.94% to $41000.0 in 2023, then skyrocketed by 341.46% to $181000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLS's Non Operating Income are $181000.0 (Q4 2024), $221000.0 (Q3 2024), and $151000.0 (Q2 2024).